Extending Platform Utility – iBio’s president, Robert Erwin, will address the Plenary Session on June 8 to describe how iBio has used its iBioLaunch platform together with the GRAMMR® technology of Novici Biotech, iBio’s contract partner, to enable the development of products that would otherwise be biologically or economically infeasible by overcoming yield limitations, increasing formulation flexibility, and increasing product value. Mr. Erwin will provide examples of recent successes with antibodies and other therapeutic proteins relevant to iBio’s commercial strategy.
Progress with IBIO-CFB03 for Treatment of Fibrotic Disease – On June 8, iBio’s Chief Scientific Officer, Dr. Terence Ryan, will explain the rationale for iBio’s selection of iBIO-CFB03 as its lead clinical candidate for its first fibrotic disease indication. He will describe the use of iBioLaunch technology to create recombinant versions of its peptide product that initially was chemically synthesized and how the iBioLaunch-produced recombinant versions are at least equally efficacious but more efficient and less expensive to produce than the original synthesized product. Dr. Ryan also will provide an update on iBio’s clinical strategy and timeline for iBio’s fibrotic disease product portfolio.
Use of iBioLaunch Technology for Antibody Optimization and Production – On June 9, iBio’s collaborator, Dr. R. Barry Holtz, will discuss the use of the iBioLaunch platform to produce anti-viral antibodies in plants at Caliber Biotherapeutics for potential therapeutic and preventative applications. He will describe successes achieved to substantially increase the yield and enhance the therapeutic effectiveness of certain antibodies, including a specific case study that resulted in superior performance of an antibody made in plants when compared directly to its CHO (Chinese Hamster Ovary Cell) produced counterpart. Dr. Holtz’s past work with the iBioLaunch platform has included its application to antibodies targeting the Ebola virus, Dengue fever viruses, and various forms of cancer.
About the PBVAB 2015 Conference
PBVAB 2015 is the sixth meeting in this important and successful series. PBVAB 2015 will offer an international forum to review the current state of research in plant protein expression systems, down-stream processing technology, the pipeline of products now in development (including vaccines, monoclonal antibodies, and human enzymes), and efforts in using these technologies in areas beyond human health (including disease prevention in animals and aquaculture). PBVAB 2015 will aim to attract an international audience of researchers, clinicians, and representatives for academia, industry and government/regulatory/public health organizations. Representatives for the human, veterinary, plant communities with an interest in vaccinology, immunology, biotechnology issues in relation to plant-based systems will find PBVAB 2015 of value.
About iBio, Inc.
iBio is developing proprietary products for the treatment of a range of fibrotic diseases including idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. IBIO-CFB03, produced using the company’s iBioLaunch™ gene expression platform, is the first product candidate from this program designated for IND development. The company also offers proprietary products and product licenses to others, based on its proprietary iBioLaunch™ gene expression and iBioModulator™ thermostable immunomodulator protein platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has formed a subsidiary company, iBio do Brasil Biofarmaceutical Ltda., and has been collaborating with the Oswaldo Cruz Foundation (Fiocruz) to develop a recombinant yellow fever vaccine based on iBio technology. The iBioLaunch™ gene expression platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator™ platform is designed to significantly improve vaccine products with both higher potency and greater duration of effect. Further information is available at: www.ibioinc.com.
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY’S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY’S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY’S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.